Developer docs
API playgroundTry for free, no card

Search company profiles

Diagonal Therapeutics

Full company profile

uuid0000c4o

Namestring
Diagonal Therapeutics
Legal namestring
Diagonal Therapeutics, Inc.
Websiteurl
diagonaltx.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Diagonal Therapeutics is a clinical-stage biotechnology company developing first-in-class clustering antibody therapeutics that address the root cause of genetic diseases caused by impaired receptor signaling. Founded in 2022 and headquartered in Watertown, Massachusetts, the company emerged from stealth in April 2024 with a $128 million Series A financing. Diagonal targets rare diseases — primarily hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH) — for which no disease-modifying therapies currently exist. Its lead asset, DIAG723, is a bispecific clustering antibody in IND-enabling studies that restores ALK1:BMPRII signaling on endothelial cells, with first-in-human trials planned for the first half of 2026.

The company's core innovation is the DIAGONAL Product Engine, a proprietary platform that combines computational and experimental techniques to discover agonist antibodies capable of binding two or more receptors and bringing them together in specific conformations to activate or inhibit downstream signaling. The platform generates immune repertoires of approximately 200,000 distinct antibody sequences per target, computationally evaluates over 10 billion possible multi-specific antibody combinations, and uses shape clustering and binning by complementarity to identify therapeutic candidates. Preclinical data demonstrated that DIAG723 improved survival from 25% to 100% in HHT mouse models and outperformed sildenafil on key hemodynamic parameters in PAH rat models. Beyond DIAG723, the pipeline includes undisclosed preclinical programs in venous malformations, iron overload, and chronic kidney disease.

Diagonal is pre-revenue and operates a clinical-stage biotech business model with no commercial products. Future revenue is expected from sales of proprietary drug products following regulatory approval, initially through specialty pharmacy and hospital channels typical of orphan/rare disease therapeutics. The company has raised over $253 million across two financing rounds from a syndicate that includes Atlas Venture, BVF Partners, Sanofi Ventures, Janus Henderson Investors, RA Capital Management, Frazier Life Sciences, and Viking Global Investors. Strategic partnerships include the HHT IMPACT natural history study with Cure HHT and research collaborations with Massachusetts General Hospital/Harvard Medical School and the Feinstein Institutes for Medical Research. The company has received Orphan Drug Designation from both the U.S. FDA and the EMA for DIAG723 in HHT.

Short descriptiontext

Diagonal Therapeutics is a clinical-stage biotechnology company developing first-in-class clustering antibody therapeutics to treat rare genetic diseases including hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension, using its proprietary DIAGONAL Product Engine platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clustering antibody therapeutics, rare disease drug discovery, agonist antibody platform, bispecific antibody engineering, orphan genetic disease therapy
Industry3 codes
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in the Physical, Engineering, and Life Sciences54171
Product category
Biotechnology Therapeutics — Rare Genetic Disease Antibodies
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Diagonal Therapeutics is a pre-revenue clinical-stage biotechnology company developing clustering antibody therapeutics. The company does not yet have approved products or commercial revenue. Revenue is expected to be generated through sales of proprietary drug products following regulatory approval for the treatment of rare diseases such as HHT and PAH.

diagonaltx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Diagonal Therapeutics is a clinical-stage biotechnology company developing clustering (agonist) antibody therapeutics for rare genetic diseases caused by impaired receptor signaling. Its lead candidate DIAG723 is a bispecific clustering antibody designed to restore ALK1:BMPRII signaling for treatment of hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH). Drug discovery is enabled by the proprietary DIAGONAL Product Engine, which combines computational and experimental techniques to identify clustering antibodies from billions of possible receptor-binding combinations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • In preclinical HHT models (BMP9/10-deficient mice, ENG-deficient mice, haploinsufficient ALK1 mice), DIAG723 prevented and reversed AVM pathology, prevented HHT-associated anemia and heart enlargement, and improved survival from 25% to 100%.
+3 more records
Product overview1 text field

Diagonal Therapeutics is a biotechnology company pioneering a new approach to discovering and developing clustering agonist antibodies that address the root cause of genetic diseases. The company's core offering centers on its proprietary DIAGONAL Product Engine, which combines computational and experimental techniques to identify clustering antibodies that regulate signaling cascades by binding multiple receptors in specific conformations. The lead product is DIAG723, a first-in-class bispecific clustering antibody in IND-enabling stage for hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH). The pipeline spans multiple therapeutic areas including vasculopathy (HHT, PAH, venous malformations), hepatology (iron overload), and nephrology (chronic kidney disease), with programs at preclinical and IND-enabling stages.

Product and service4 records
1DIAG723
CategoryBispecific antibody therapeutic (lead clinical candidate)
Description

First-in-class bispecific clustering antibody designed to restore ALK1 signaling by clustering ALK1 and BMPRII receptors on endothelial cells; in IND-enabling studies for treatment of HHT and PAH.

2Undisclosed Venous Malformations Program
CategoryPipeline program (vasculopathy)
Description

Preclinical clustering antibody program targeting vascular malformations within the vasculopathy therapeutic area.

3Undisclosed Iron Overload Program
CategoryPipeline program (hepatology)
Description

Preclinical clustering antibody program in hepatology addressing iron overload conditions caused by impaired receptor signaling.

4Undisclosed Chronic Kidney Disease Program
CategoryPipeline program (renal)
Description

Preclinical clustering antibody program in nephrology addressing chronic kidney disease caused by impaired receptor signaling.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-04
Description

Diagonal Therapeutics partnered with Cure HHT, the leading international patient advocacy organization for hereditary hemorrhagic telangiectasia, to launch the HHT IMPACT natural history study — a non-interventional, observational, longitudinal evaluation characterizing patient-reported outcomes including epistaxis, hematologic support, and quality of life in adults with HHT. The study enrolled 109 patients and will inform the design of future clinical trials for DIAG723. Cure HHT also hosted Diagonal at its 15th International Scientific Conference in 2024.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Diagonal collaborated with Dr. Hanny Al-Samkari (Peggy S. Blitz Endowed Chair in Hematology/Oncology at MGH and Associate Professor of Medicine at Harvard Medical School) on health economics and outcomes research characterizing the cost and clinical burden of HHT patients. The study was published in the American Journal of Hematology and leveraged Komodo Health's Healthcare Map claims database covering 330+ million patients.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Diagonal collaborated with Philippe Marambaud, Ph.D. (Professor, Institute of Molecular Medicine, Feinstein Institutes for Medical Research) on preclinical research demonstrating the disease-modifying potential of DIAG723's clustering antibody approach in HHT models. Dr. Marambaud presented invited talks at EHA 2025 and Cure HHT's 15th International Scientific Conference.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing novel bispecific/multispecific antibodies for atopic dermatitis, asthma, and other inflammatory/rare diseases — directly comparable antibody platform and rare/specialty-disease GTM to Diagonal's lead program focus.

TypeDirect peer
Description

Late-clinical biotech developing monoclonal antibodies for rare neuromuscular diseases (e.g., spinal muscular atrophy), with an antibody platform approach to validated signaling pathways — closely comparable as a rare-disease antibody platform company.

TypeDirect peer
Description

Clinical-stage biotech developing bispecific antibodies against novel targets in oncology — directly comparable in its use of bispecific/multispecific antibody engineering to address diseases caused by aberrant receptor signaling.

TypeBroad incumbent
Description

Large established biotech whose proprietary DuoBody and HexaBody platforms are industry-standard bispecific/multispecific antibody technologies; comparable platform-level R&D but as a much larger, established player with approved products.

TypeBroad incumbent
Description

Established clinical-stage biotech commercializing its Azymetric and EffiFunction bispecific/multispecific antibody platforms — directly comparable antibody engineering platform with broader pipeline scope and partnerships across multiple pharma.

TypeDirect peer
Description

Clinical-stage biotech developing bispecific T cell engagers (TRACTr platform) for cancer, recently acquired by Merck — closely comparable as a bispecific antibody platform biotech with high-multiple pharma acquirer interest.

TypeEmerging player
Description

Clinical-stage biotech developing targeted therapeutics for cancer with a focused, asset-centric model — comparable in stage and strategic approach for advancing precision therapeutics in high-unmet-need indications.

TypeOthers
Description

Commercial-stage biotech with a genetic-disease focus and first-to-market orphan product (Vyjuvek for DEB) — comparable in size and rare-disease commercial focus but uses gene therapy rather than antibody modality.

TypeBroad incumbent
Description

Large, multi-asset biotech platform operator with several subsidiaries (including antibody-focused ones) targeting rare and specialty diseases — comparable platform-company model and rare-disease commercial orientation, but much larger and more diversified.

TypeEmerging player
Description

Clinical-stage biotech whose PowerCision and NEObody platforms use computational methods to engineer antibodies for oncology — adjacent platform comparison given Diagonal's also-computational approach to multi-specific antibody discovery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Diagonal Therapeutics

Biotechnology Therapeutics — Rare Genetic Disease Antibodiesdiagonaltx.com

Diagonal Therapeutics is a clinical-stage biotechnology company developing first-in-class clustering antibody therapeutics to treat rare genetic diseases including hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension, using its proprietary DIAGONAL Product Engine platform.

What Diagonal Therapeutics does

Diagonal Therapeutics is a clinical-stage biotechnology company developing first-in-class clustering antibody therapeutics that address the root cause of genetic diseases caused by impaired receptor signaling. Founded in 2022 and headquartered in Watertown, Massachusetts, the company emerged from stealth in April 2024 with a $128 million Series A financing. Diagonal targets rare diseases — primarily hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH) — for which no disease-modifying therapies currently exist. Its lead asset, DIAG723, is a bispecific clustering antibody in IND-enabling studies that restores ALK1:BMPRII signaling on endothelial cells, with first-in-human trials planned for the first half of 2026.

The company's core innovation is the DIAGONAL Product Engine, a proprietary platform that combines computational and experimental techniques to discover agonist antibodies capable of binding two or more receptors and bringing them together in specific conformations to activate or inhibit downstream signaling. The platform generates immune repertoires of approximately 200,000 distinct antibody sequences per target, computationally evaluates over 10 billion possible multi-specific antibody combinations, and uses shape clustering and binning by complementarity to identify therapeutic candidates. Preclinical data demonstrated that DIAG723 improved survival from 25% to 100% in HHT mouse models and outperformed sildenafil on key hemodynamic parameters in PAH rat models. Beyond DIAG723, the pipeline includes undisclosed preclinical programs in venous malformations, iron overload, and chronic kidney disease.

Diagonal is pre-revenue and operates a clinical-stage biotech business model with no commercial products. Future revenue is expected from sales of proprietary drug products following regulatory approval, initially through specialty pharmacy and hospital channels typical of orphan/rare disease therapeutics. The company has raised over $253 million across two financing rounds from a syndicate that includes Atlas Venture, BVF Partners, Sanofi Ventures, Janus Henderson Investors, RA Capital Management, Frazier Life Sciences, and Viking Global Investors. Strategic partnerships include the HHT IMPACT natural history study with Cure HHT and research collaborations with Massachusetts General Hospital/Harvard Medical School and the Feinstein Institutes for Medical Research. The company has received Orphan Drug Designation from both the U.S. FDA and the EMA for DIAG723 in HHT.

Diagonal Therapeutics firmographics

Firmographics
Name
Diagonal Therapeutics
Legal name
Diagonal Therapeutics, Inc.
Website
https://diagonaltx.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Short description
Diagonal Therapeutics is a clinical-stage biotechnology company developing first-in-class clustering antibody therapeutics to treat rare genetic diseases including hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension, using its proprietary DIAGONAL Product Engine platform.
Ownership category
akta.pro rank

Diagonal Therapeutics industry classification

Industry
Product category
Biotechnology Therapeutics — Rare Genetic Disease Antibodies
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Clustering antibody therapeutics
  • Rare disease drug discovery
  • Agonist antibody platform
  • Bispecific antibody engineering
  • Orphan genetic disease therapy

Where Diagonal Therapeutics is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Diagonal Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Revenue: Diagonal Therapeutics is a pre-revenue clinical-stage biotechnology company developing clustering antibody therapeutics. The company does not yet have approved products or commercial revenue. Revenue is expected to be generated through sales of proprietary drug products following regulatory approval for the treatment of rare diseases such as HHT and PAH.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Diagonal Therapeutics product offering

Product offering

Core offering

Diagonal Therapeutics is a clinical-stage biotechnology company developing clustering (agonist) antibody therapeutics for rare genetic diseases caused by impaired receptor signaling. Its lead candidate DIAG723 is a bispecific clustering antibody designed to restore ALK1:BMPRII signaling for treatment of hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH). Drug discovery is enabled by the proprietary DIAGONAL Product Engine, which combines computational and experimental techniques to identify clustering antibodies from billions of possible receptor-binding combinations.

Product overview

Diagonal Therapeutics is a biotechnology company pioneering a new approach to discovering and developing clustering agonist antibodies that address the root cause of genetic diseases. The company's core offering centers on its proprietary DIAGONAL Product Engine, which combines computational and experimental techniques to identify clustering antibodies that regulate signaling cascades by binding multiple receptors in specific conformations. The lead product is DIAG723, a first-in-class bispecific clustering antibody in IND-enabling stage for hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH). The pipeline spans multiple therapeutic areas including vasculopathy (HHT, PAH, venous malformations), hepatology (iron overload), and nephrology (chronic kidney disease), with programs at preclinical and IND-enabling stages.

Differentiator

Problem solved

Functional benefit

Products and services

  • DIAG723 First-in-class bispecific clustering antibody designed to restore ALK1 signaling by clustering ALK1 and BMPRII receptors on endothelial cells; in IND-enabling studies for treatment of HHT and PAH.
  • Undisclosed Venous Malformations Program Preclinical clustering antibody program targeting vascular malformations within the vasculopathy therapeutic area.
  • Undisclosed Iron Overload Program Preclinical clustering antibody program in hepatology addressing iron overload conditions caused by impaired receptor signaling.
  • Undisclosed Chronic Kidney Disease Program Preclinical clustering antibody program in nephrology addressing chronic kidney disease caused by impaired receptor signaling.

Quantifiable outcome

  • In preclinical HHT models (BMP9/10-deficient mice, ENG-deficient mice, haploinsufficient ALK1 mice), DIAG723 prevented and reversed AVM pathology, prevented HHT-associated anemia and heart enlargement, and improved survival from 25% to 100%.
  • +3 more outcomes

Companies that use Diagonal Therapeutics

Customer profile

Segments3 records

Ideal customer profiles3 records

Diagonal Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature1 record

Diagonal Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and supporting.

  • Cure HHTcoreStrategic or Co-development Partner · 4 March 2025Diagonal Therapeutics partnered with Cure HHT, the leading international patient advocacy organization for hereditary hemorrhagic telangiectasia, to launch the HHT IMPACT natural history study — a non-interventional, observational, longitudinal evaluation characterizing patient-reported outcomes including epistaxis, hematologic support, and quality of life in adults with HHT. The study enrolled 109 patients and will inform the design of future clinical trials for DIAG723. Cure HHT also hosted Diagonal at its 15th International Scientific Conference in 2024.
  • Massachusetts General Hospital / Harvard Medical SchoolcoreStrategic or Co-development PartnerDiagonal collaborated with Dr. Hanny Al-Samkari (Peggy S. Blitz Endowed Chair in Hematology/Oncology at MGH and Associate Professor of Medicine at Harvard Medical School) on health economics and outcomes research characterizing the cost and clinical burden of HHT patients. The study was published in the American Journal of Hematology and leveraged Komodo Health's Healthcare Map claims database covering 330+ million patients.
  • Feinstein Institutes for Medical ResearchsupportingStrategic or Co-development PartnerDiagonal collaborated with Philippe Marambaud, Ph.D. (Professor, Institute of Molecular Medicine, Feinstein Institutes for Medical Research) on preclinical research demonstrating the disease-modifying potential of DIAG723's clustering antibody approach in HHT models. Dr. Marambaud presented invited talks at EHA 2025 and Cure HHT's 15th International Scientific Conference.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Diagonal Therapeutics competitors and assessment

Company assessment

Direct peers

  • Apogee Therapeutics: Clinical-stage biotech developing novel bispecific/multispecific antibodies for atopic dermatitis, asthma, and other inflammatory/rare diseases — directly comparable antibody platform and rare/specialty-disease GTM to Diagonal's lead program focus.
  • Scholar Rock: Late-clinical biotech developing monoclonal antibodies for rare neuromuscular diseases (e.g., spinal muscular atrophy), with an antibody platform approach to validated signaling pathways — closely comparable as a rare-disease antibody platform company.
  • Compass Therapeutics: Clinical-stage biotech developing bispecific antibodies against novel targets in oncology — directly comparable in its use of bispecific/multispecific antibody engineering to address diseases caused by aberrant receptor signaling.
  • Janux Therapeutics: Clinical-stage biotech developing bispecific T cell engagers (TRACTr platform) for cancer, recently acquired by Merck — closely comparable as a bispecific antibody platform biotech with high-multiple pharma acquirer interest.

Broad incumbents

  • Genmab: Large established biotech whose proprietary DuoBody and HexaBody platforms are industry-standard bispecific/multispecific antibody technologies; comparable platform-level R&D but as a much larger, established player with approved products.
  • Zymeworks: Established clinical-stage biotech commercializing its Azymetric and EffiFunction bispecific/multispecific antibody platforms — directly comparable antibody engineering platform with broader pipeline scope and partnerships across multiple pharma.
  • Roivant Sciences: Large, multi-asset biotech platform operator with several subsidiaries (including antibody-focused ones) targeting rare and specialty diseases — comparable platform-company model and rare-disease commercial orientation, but much larger and more diversified.

Emerging players

  • Cullinan Oncology: Clinical-stage biotech developing targeted therapeutics for cancer with a focused, asset-centric model — comparable in stage and strategic approach for advancing precision therapeutics in high-unmet-need indications.
  • Adagene: Clinical-stage biotech whose PowerCision and NEObody platforms use computational methods to engineer antibodies for oncology — adjacent platform comparison given Diagonal's also-computational approach to multi-specific antibody discovery.

Others

  • Krystal Biotech: Commercial-stage biotech with a genetic-disease focus and first-to-market orphan product (Vyjuvek for DEB) — comparable in size and rare-disease commercial focus but uses gene therapy rather than antibody modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Diagonal Therapeutics social profiles

Digital presence

Diagonal Therapeutics compliance and trust

Trust signal

Compliance2 records

Diagonal Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Diagonal Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

Diagonal Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Diagonal Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diagonal Therapeutics

What does Diagonal Therapeutics do?

Diagonal Therapeutics is a clinical-stage biotechnology company developing clustering (agonist) antibody therapeutics for rare genetic diseases caused by impaired receptor signaling. Its lead candidate DIAG723 is a bispecific clustering antibody designed to restore ALK1:BMPRII signaling for treatment of hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH). Drug discovery is enabled by the proprietary DIAGONAL Product Engine, which combines computational and experimental techniques to identify clustering antibodies from billions of possible receptor-binding combinations.

Is Diagonal Therapeutics a public or private company?

Diagonal Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Diagonal Therapeutics founded?

Diagonal Therapeutics was founded in 2024. It employs 11 to 50 people.

Where is Diagonal Therapeutics based?

Diagonal Therapeutics is headquartered in Watertown, United States, in the North America region.

How does Diagonal Therapeutics make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Diagonal Therapeutics's main competitors?

Direct peers on record are Apogee Therapeutics, Scholar Rock, Compass Therapeutics and Janux Therapeutics. Broad incumbents are Genmab, Zymeworks and Roivant Sciences. Emerging players are Cullinan Oncology and Adagene. Krystal Biotech is listed as an others.

Does Diagonal Therapeutics have an API?

No public API is recorded for Diagonal Therapeutics.

What industry is Diagonal Therapeutics in?

Diagonal Therapeutics's product category is Biotechnology Therapeutics — Rare Genetic Disease Antibodies. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 54171.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewDiagonal Therapeutics Appoints Industry Veteran Jeremy Bender, Ph.D., M.B.A., as Chair of the Board of DirectorsDiagonal Therapeutics appointed Jeremy Bender as chair of its board, succeeding Michael Gladstone. Bender brings over 20 years of drug development experience, including leading Day One Biopharmaceuticals. The company is advancing DIAG723 in a Phase 1/2 trial for hereditary hemorrhagic telangiectasia.Stock TitanDiagonal Therapeutics Names Jeremy Bender Board ChairDiagonal Therapeutics appointed Jeremy Bender as board chair, succeeding Michael Gladstone. Bender brings over 20 years of drug development experience, including leading Day One Biopharmaceuticals. The company is advancing DIAG723 in the DIAMOND Phase 1/2 trial for HHT and PAH.Tech TimesHHT Patients Get First Phase 3 Drug Trial After 130 Years Without TreatmentVaderis Therapeutics closed a $152 million Series B and launched HEROIC, the first global Phase 3 trial for engasertib in hereditary hemorrhagic telangiectasia. The drug showed a 41% reduction in bleeding duration in a prior proof-of-concept study. The trial aims to secure the first FDA approval for HHT.BioSpaceDiagonal Therapeutics Announces First Patient Dosed in Phase 1/2 DIAMOND Clinical Trial of DIAG723 for Hereditary Hemorrhagic Telangiectasia (HHT)Diagonal Therapeutics announced the first patient dosed in DIAMOND, a Phase 1/2 trial of DIAG723 for hereditary hemorrhagic telangiectasia (HHT). The trial enrolls up to 93 patients across three parts, with DIAG723 designed to restore ALK1 signaling. Preclinical studies showed the antibody prevented and reversed AVMs, indicating potential for disease modification.GlobeNewswireDiagonal Therapeutics Expands Executive Leadership Team, Appoints Industry Veteran Jonathan Piazza as Chief Financial OfficerDiagonal Therapeutics appointed Jonathan Piazza as Chief Financial Officer, bringing over 25 years of biotech experience including previous CFO roles at Orbital Therapeutics (acquired by Bristol Myers Squibb) and Silverback Therapeutics (where he led its IPO and merger with ARS Pharmaceuticals). The company is advancing DIAG723, a clustering antibody for hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension, into clinical development, having received orphan drug designation from both the U.S. FDA and EMA. Piazza will focus on strategic capital formation to support portfolio development as Diagonal enters what it describes as a pivotal chapter.Labiotech.euDiagonal Therapeutics’ innovative clustering antibodies for vascular diseasesDiagonal Therapeutics is developing clustering antibodies to treat genetic vasculopathies, with its lead program DIAG723 receiving Orphan Drug Designation for HHT. The company closed a $125 million Series B in January 2026, and the program is advancing toward the clinic.VC News DailyDiagonal Therapeutics Lands $125 Million Series BDiagonal Therapeutics, a biotechnology company based in Watertown, MA, announced the closing of an oversubscribed $125 million Series B financing round co-led by Sanofi Ventures and Janus Henderson Investors. Multiple new investors including Deep Track Capital, EcoR1 Capital, Logos Capital, Balyasny Asset Management, and Woodline Partners participated alongside existing investors such as Atlas Venture, Lightspeed Venture Partners, RA Capital Management, and Frazier Life Sciences. As part of the financing, Paulina Hill, Partner at Sanofi Ventures, will join Diagonal's Board of Directors.Pulse 2.0Diagonal Therapeutics: $125 Million Series B Raised To Advance DIAG723 Clustering Antibody Into the ClinicDiagonal Therapeutics announced it has raised $125 million in an oversubscribed Series B financing round, co-led by Sanofi Ventures and Janus Henderson Investors, to advance its lead program DIAG723 into clinical trials. DIAG723 is a first-in-class clustering antibody designed to treat hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH) by restoring ALK1 signaling in endothelial cells. The company expects to initiate first-in-human studies in HHT patients during the first half of 2026, with the funding also supporting expansion of its broader clustering-antibody pipeline.FinSMEsDiagonal Therapeutics Raises $125M in Series B FinancingDiagonal Therapeutics, a Watertown, Massachusetts-based biotechnology company, raised $125 million in Series B financing co-led by Sanofi Ventures and Janus Henderson Investors. The funding will support advancement of DIAG723, a first-in-class disease-modifying clustering antibody targeting hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension. Paulina Hill of Sanofi Ventures will join Diagonal's Board of Directors in connection with the financing.pharmaphorumParabilis scores $305m in bumper biofinancing weekParabilis Medicines (formerly FogPharma) has secured a $305 million Series F funding round led by RA Capital Management, Fidelity Management & Research, and Janus Henderson Investors to advance pivotal trials of zolucatetide (FOG-001), a beta-catenin inhibitor for desmoid tumours, and bring other candidates into clinical testing. The company, based in Cambridge, Massachusetts, had previously raised $145 million under the FogPharma name in 2022. This financing week saw five other biotech companies each raising $100 million or more, including Soley Therapeutics ($200M), Alveus Therapeutics ($160M Series A), Diagonal Therapeutics ($125M Series B), EpiBiologics ($107M Series B), and Rakuten Medical ($100M Series F).